Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M104227200 on August 29, 2001

J. Biol. Chem., Vol. 276, Issue 45, 42276-42286, November 9, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/45/42276    most recent
M104227200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamberti, C.
Right arrow Articles by Gaynor, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamberti, C.
Right arrow Articles by Gaynor, R. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Regulation of beta -Catenin Function by the Ikappa B Kinases*

Carmela LambertiDagger §, Keng-Mean LinDagger §, Yumi YamamotoDagger §, Udit VermaDagger , Inder M. Verma, Steven Byers||, and Richard B. GaynorDagger **

From the Dagger  Division of Hematology-Oncology, Department of Medicine, Harold Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390,  Salk Institute, La Jolla, California 92037, and the || Departments of Cell Biology and Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, D. C. 20007

Received for publication, May 10, 2001, and in revised form, August 28, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Both the beta -catenin and the nuclear factor kappa B (NF-kappa B) proteins are important regulators of gene expression and cellular proliferation. Two kinases, IKKalpha and IKKbeta , are critical activators of the NF-kappa B pathway. Here we present evidence that these kinases are also important in the regulation of beta -catenin function. IKKalpha - and IKKbeta -deficient mouse embryo fibroblasts exhibited different patterns of beta -catenin cellular localization. IKKbeta decreases beta -catenin-dependent transcriptional activation, while IKKalpha increases beta -catenin-dependent transcriptional activity. IKKalpha and IKKbeta interact with and phosphorylate beta -catenin using both in vitro and in vivo assays. Our results suggest that differential interactions of beta -catenin with IKKalpha and IKKbeta may in part be responsible for regulating beta -catenin protein levels and cellular localization and integrating signaling events between the NF-kappa B and Wingless pathways.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

beta -Catenin, the mammalian homologue of the Drosophila armadillo protein, is a ubiquitously expressed protein that has at least two distinct roles in the cell. First, it participates in cell-cell adhesion by mediating the association of E-cadherin with the cytoskeleton (1, 2). Second, it is a critical downstream component of the Wnt1 or Wingless signal transduction pathway (3-5). The Wnt family of secretory glycoproteins plays an important role in embryonic development, in the induction of cell polarity, and in the determination of cell fate. Deregulation of Wnt signaling disrupts axis formation in embryos (5-8) and is associated with multiple human malignancies (9).

The current model of Wnt signaling indicates that the binding of the Wnt proteins to their receptor, frizzled, stabilizes beta -catenin by inhibiting the activity of a serine/threonine kinase glycogen synthase kinase-3 or GSK-3beta (9). GSK-3beta is associated with beta -catenin in a multiprotein complex that includes the adenomatous polyposis coli tumor suppressor protein (APC), axin or conductin, protein phosphatase 2A, and dishevelled. GSK-3beta phosphorylation of residues in the amino terminus of beta -catenin results in APC-mediated beta -catenin degradation via the ubiquitin-proteosome pathway (10, 11). Increased levels of beta -catenin are frequently found in colon cancer due to mutations in either the APC gene (12-14) or at residues in the amino terminus of beta -catenin that are phosphorylated by GSK-3beta (15-17). In the nucleus, beta -catenin forms a complex with members of the T-cell factor (TCF)/lymphocyte-enhancer factor (LEF) family and activates gene expression of a variety of target genes (18-23) including c-myc (24) and cyclin D1 (25, 26).

NF-kappa B comprises a family of transcription factors which are critical in activating the expression of genes involved in the immune and inflammatory response and in the regulation of cellular apoptosis (27, 28). NF-kappa B is sequestered in the cytoplasm by a family of inhibitory proteins known as Ikappa B. Upon stimulation of this pathway by a variety of agents including IL-1 and TNFalpha , the kinases IKKalpha and IKKbeta (29-33) in conjunction with the scaffold protein IKKgamma /NEMO (34-36) leads to the phosphorylation of Ikappa Balpha at serine residues 32 and 36. Gene disruption studies in mice indicate that IKKbeta appears to be the critical kinase in activating the NF-kappa B pathway (37-39), while IKKalpha appears to be critical for other functions such as keratinocyte differentiation (40-42). IKKalpha and IKKbeta can form homodimers and also heterodimerize with each other, and this process is critical for their kinase activity. IKK phosphorylation of Ikappa Balpha leads to its ubiquitination and degradation by the 26S proteasome and the nuclear translocation of NF-kappa B (43).

Interestingly, the sequence DSGXXS, which is the target site in Ikappa B for IKK phosphorylation, is also found in the amino terminus of beta -catenin (11). Phosphorylation of this sequence in both beta -catenin and Ikappa B stimulates their interactions with the ubiquitin ligase beta -TrCP leading to their degradation by the proteasome (10, 11, 44). It has also been demonstrated that the beta -catenin/TCF complex increases beta -TrCP levels by a posttranscriptional mechanism to result in opposite effects on beta -catenin and NF-kappa B activity (45). In addition, disruption of either the murine GSK-3beta and IKKbeta genes result in a similar phenotype with embryonic lethality due to hepatic apoptosis from increased sensitivity to TNFalpha (46). These results suggest potential relationships between beta -catenin and NF-kappa B signaling pathways.

Given the fact that both the NF-kappa B and beta -catenin pathways are important in the control of cellular proliferation and are regulated by cellular kinases that lead to beta -TrCP-mediated degradation (10, 11, 45), we explored potential similarities in their regulation. First, we addressed whether there were differences in the cellular localization of beta -catenin in wild-type mouse embryo fibroblasts as compared with fibroblasts derived from IKKalpha - and IKKbeta -deficient mice. Next, we analyzed interactions between both IKKalpha and IKKbeta and beta -catenin and determined whether these kinases regulated beta -catenin-dependent transcriptional activity. The results of this analysis indicate that IKKalpha can positively regulate beta -catenin-dependent transcriptional activity while IKKbeta negatively regulates this activity.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cells and Reagents-- SW480 cells were purchased from American Tissue Culture Collection (Manassas, VA) and maintained in L-15 medium supplemented with 10% fetal bovine serum (HyClone Laboratories), 2 mM L-glutamine, and antibiotics (penicillin-streptomycin). COS, mouse embryo fibroblasts (MEFs, a kind gift of Xiaodong Wong), IKKalpha and IKKbeta knock-out cells (39, 42) were maintained in Dulbecco's modified Eagle's medium and supplemented with the same components as above.

Antibodies-- Polyclonal antibodies to IKKalpha (sc-7182), IKKbeta (sc-7607), and beta -catenin (sc-1496) were obtained from Santa Cruz Biotechnology. Monoclonal antibodies against beta -catenin and TFIIB (Transduction Laboratory), IKKalpha (PharMingen), the hemagglutinin epitope HA/12CA5 (Roche Molecular Biochemicals), and the FLAG-epitope-M2 (Sigma) were also used in immunoprecipitation and Western blot analysis. Donkey anti-rabbit, anti-mouse and anti-goat antibodies conjugated with either anti-FITC or Red-X rhodamine were obtained from Jackson Laboratory.

Plasmid Constructs-- The pCMV5 expression plasmids containing either FLAG-tagged IKKalpha and IKKbeta including the constitutively active kinases (SS/EE) with substitutions at residues 176/180 for IKKalpha or 177/181 for IKKbeta and the kinase defective (K/M) mutants at residue 44 in both IKKalpha and IKKbeta were described previously (30, 47, 48). Wild-type and mutant IKKalpha and IKKbeta cDNAs were each cloned into the baculovirus expression vector pAcHLT. The recombinant baculoviruses were used to infect SF9 cells to produce recombinant IKK proteins for in vitro kinase assays (48). The pCMV5 expression vectors containing the wild-type and the dominant negative NIK mutant in which lysine residues at positions 429 and 430 were substituted with alanine contained an amino-terminal Myc-tag (48).

The pCMV5 expression vectors encoding full-length human beta -catenin was provided by S. Byers, while the plasmids for LEF-1, TOPFLASH, and FOPFLASH were gifts of K. Kinzler and R. Grosschedl. The RSV-beta -galactosidase construct was a gift from P. Chaudhary. The glutathione S-transferase (GST) full-length beta -catenin (GST beta -cat-(1-781)) bacterial expression vector was constructed by using polymerase chain reaction (PCR) to generate a fragment encompassing the full-length beta -catenin, which was then cloned in frame with GST in the pGEX. The GST fusion protein containing the amino-terminal 91 amino acids of beta -catenin was constructed by SacI digestion and ligation of the GST fusion containing wild-type beta -catenin. The constructs GST-beta -cat-(130-781), GST-beta -cat-(1-400), GST-beta -cat-(130-400), and GST-beta -cat-(618-781) were constructed using PCR. The amino-terminal deleted form of beta -catenin utilized PCR primers to generate a fragment containing amino acids 130-781, which was cloned into pCMV5 and contained a carboxyl-terminal HA-epitope. All constructs that were generated by PCR were subjected to DNA sequencing and cloned into pcDNA3.

Expression and Purification of GST beta -Catenin Fusion Proteins-- Recombinant GST beta -catenin fusion proteins were expressed in bacterial strain BL21 and lysed in HMK buffer (50 mM Tris (pH 7.5), 0.1 M NaCl, 1 mM phenylmethylsulfonyl fluoride), and the bacterial lysates were incubated with 0.5 ml of packed glutathione-conjugated-agarose beads (Sigma) for 2 h at 4 °C. After three washes, the GST fusion proteins were eluted with 10 mM glutathione in HMK buffer and dialyzed, and protein purity was assessed by SDS-polyacrylamide gel electrophoresis.

Luciferase Reporter Assays-- COS cells and mouse embryo fibroblasts were plated at 50% confluence in 35-mm tissue culture wells. After 24 h, the cells were transfected using LipofectAMINE Plus with the indicated DNA constructs and either the TOPFLASH luciferase reporter containing LEF/TCF binding sites or the FOPFLASH luciferase reporter with mutated LEF/TCF sites. An NF-kappa B luciferase reporter containing three NF-kappa B binding sites upstream of a thymidine kinase minimal promoter was used to detect NF-kappa B-directed gene expression. An RSV-beta -galactosidase expression vector was included in the transfection assays to control for differences in transfection efficiency, and the pCMV5 plasmid was added to the transfection assays to standardize DNA quantities. Between 18 to 24 h posttransfection, the cells were washed twice with cold PBS, and the reporter activity was measured using the luciferase assay system (Promega). All transfections were done in duplicate and repeated at least three times.

Fractionation of Cellular Extracts-- Cytoplasmic extracts were prepared from 108 SW480 or COS cells as described previously (49) with slight modifications. Cells were washed twice with cold PBS, and cell pellets were resuspended in 5 volumes of buffer A (10 mM Hepes (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM EDTA) supplemented with phosphatase inhibitors (10 mM NaF, 10 mM beta -glycerophosphate, 0.5 µM okadaic acid, 1 mM sodium orthovanadate), and protease inhibitors (Roche Molecular Biochemicals). After incubation on ice for 10 min, cells were lysed with 15 strokes of a Wheaton all-glass Dounce homogenizer (Tight pestle). Nuclei were pelleted by centrifugation for 5 min at 2000 rpm (Beckman bench-top centrifuge, CH3.7 rotor). The supernatants termed S100 were collected, mixed with 0.11 volume of buffer B (0.3 M Hepes (pH 7.9), 30 mM MgCl2, and 1.4 M NaCl), and then centrifuged at 100,000 × g for 60 min at 4 °C.

Whole cell extracts were prepared from COS cells transfected with hemagglutinin-tagged beta -catenin alone or beta -catenin and FLAG-tagged IKKalpha and IKKbeta as described (47) in lysis buffer containing 40 mM Tris, (pH 8), 500 mM NaCl, 0.1% Nonidet P-40, 6 mM EDTA, 6 mM EGTA, 5 mM beta -glycerophosphate, 5 mM NaF, 1 mM NaVO4 (pH 10.0), and protease inhibitors (Roche Molecular Biochemicals).

Gel Filtration Chromatography-- S100 extracts prepared from the SW480 and COS cells were further fractionated on a Superdex-200 gel filtration column (Amersham Pharmacia Biotech) and equilibrated with buffer D (20 mM Hepes (pH 7.9), 0.1 M KCl, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 0.2 mM EDTA, 20% glycerol). Protein markers (Sigma) used for the calibration of the column included bovine thyroglobulin (669 kDa), horse spleen apoferritin (443 kDa), beta -amylase (200 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), and cytochrome c (12.5 kDa).

Protein Association and Western Blot Analysis-- For endogenous protein association studies, equal volumes of proteins (200-300 µl) from each of the Superdex-200 fraction were incubated overnight at 4 °C with 1 µg of indicated antibodies or normal mouse IgG followed by the addition of protein G-agarose (Sigma) for 2-3 h at 4 °C. For protein association studies using transfected IKK and beta -catenin expression vectors, COS cells were transfected with FLAG-tagged IKKalpha or IKKbeta and HA-tagged beta -catenin cDNAs. Cells were harvested 18-24 h after transfection, extracts were prepared, and gel chromatography was performed as described above. Equal volumes of each column fraction were immunoprecipitated with 12CA5 antibody or anti-FLAG M2 antibody. Immunoprecipitates were resolved by SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes (Amersham Pharmacia Biotech), and probed with specific antibodies. The membrane-bound immune complexes were analyzed with an enhanced chemiluminescence system (Amersham Pharmacia Biotech). For in vitro association studies, 40 µl of the cytoplasmic fractions were incubated overnight at 4 °C with 40 µl of the glutathione-conjugated-agarose bound with indicated proteins. Following three washes with 10 volumes of cold PBS, the protein complexes were subjected to Western blot analysis as described above.

In Vitro Kinase Assays-- Kinase assays were performed as described by Yamamoto et al. (48). The baculovirus-produced IKK proteins were purified by nickel-agarose chromatography and then immunoprecipitated with 12CA5 monoclonal antibody (48). The epitope-tagged IKKalpha and IKKbeta kinases were transfected into COS cells, and extracts were immunoprecipitated with the M2 monoclonal antibody directed against the FLAG-epitope. These kinases were added to kinase buffer containing 10 µCi of [gamma -32P]ATP, 1 mM ATP, 1 mM dithiothreitol, 5 mM MgCl2, 100 mM NaCl, 50 mM Tris-HCl (pH 8.0), and then 1 µg of each of the substrates including wild-type or the S32A/S36A of GST-Ikappa Balpha -(1-54) or GST-beta -cat-(1-91) were incubated for 15 min at 30 °C. For determination of phosphate incorporation into the GST-Ikappa Balpha -(1-54) and GST-beta -catenin-(1-91), 2 µg of each of these substrates was incubated with either FLAG-tagged IKKalpha or IKKbeta , which were immunoprecipitated from COS cell extract with the M2 monoclonal antibody in kinase buffer containing 15 µCi of [gamma -32P]ATP with a specific activity of 6000 Ci/mM (New England Nuclear) and either 0.01 mM, 0.01 mM, or 1.0 mM of cold ATP. The kinase reaction mixtures were subjected to electrophoresis on 10% SDS-polyacrylamide gels and autoradiography. The 32P-labeled Ikappa Balpha and beta -catenin substrates were then subjected to scintillation counting, and the moles of phosphate incorporated were calculated. Reactions were incubated at 30 °C for 5, 15, 30, 60, and 120 min and stopped by the addition of protein loading buffer and heating to 90 °C.

Immunocytochemistry and Confocal Microscopy-- Cells were cultured overnight on coverslips in Dulbecco's modified Eagle's medium without serum, washed two times with PBS, and fixed with 3.7% formaldehyde for 10 min followed by a brief permeabilization with 0.5% Triton X-100 in PBS. The cells were blocked for 30 min with 3% normal donkey serum in PBS and then incubated for 1 h with primary antibodies (diluted 1:50 to 1:200 in 1% normal donkey serum in PBS). The coverslips were washed three times with PBS and then incubated for 1 h with the secondary antibodies conjugated with FITC or Red-X rhodamine (diluted 1:400 in 1% normal donkey serum in PBS). Samples were washed three times and then treated with Aquamount (Polysciences). The results were analyzed on a laser scanning confocal microscope MRC 1000 (Bio-Rad).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

beta -Catenin Localization in IKK-deficient Cells-- First, the localization of IKKalpha and IKKbeta in wild-type MEFs was compared with that seen in IKKalpha -deficient (IKKalpha -/-) and IKKbeta -deficient (IKKbeta -/-) cells using immunofluorescence analysis with confocal microscopy. Wild-type mouse embryo fibroblasts (Fig. 1A, panels A and B), IKKalpha -/- (Fig. 1A, C and D), and IKKbeta -/- (Fig. 1A, panels E and F) cells were plated on coverslips overnight and stained with rabbit polyclonal antibodies directed against either IKKalpha or IKKbeta . In MEFs, IKKalpha localized in both the nucleus and the cytoplasm, while IKKbeta localized predominantly in the cytoplasm (Fig. 1A, panels A and B). In IKKalpha -/- cells, IKKbeta localized predominantly in the cytoplasm (Fig. 1A, panel D). In IKKbeta -/- cells, there appeared to be increased IKKalpha present in the nucleus as compared with that seen in MEFs (Fig. 1A, panel E). There was no IKKalpha staining observed in IKKalpha -/- cells (Fig. 1A, panel C) or IKKbeta staining seen in IKKbeta -/- (Fig. 1A, panel F), thus confirming the identity of these cells.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of beta -catenin localization in IKKalpha - and IKKbeta -deficient cells. A, MEF (panels A and B) and either IKKalpha -deficient (IKKalpha -/-) (panels C and D) or IKKbeta -deficient (IKKbeta -/-) (panels E and F) embryo fibroblasts were plated overnight on coverslips before staining with either rabbit polyclonal antibodies directed against IKKalpha (panels A, C, and E) or IKKbeta (panels B, D, and F) followed by staining with a secondary Red-X rhodamine-conjugated rabbit antibody. B, alternatively MEF (panels A-C), IKKalpha -/- (panels D-F) and IKKbeta -/- (panels G-I) cells were stained with either a goat antibody to beta -catenin (green) (panels A, D, and G) or a mouse monoclonal antibody to TFIIB (red) (panels B, E, and H). Donkey anti-goat antibody conjugated with FITC and anti-mouse conjugated with Red-X rhodamine were used as secondary antibodies. The respective negative controls utilizing the TFIIB monoclonal antibody and the donkey anti-goat FITC-conjugated antibody are also shown (panels C, F, and I). Images were collected using a laser scanning confocal microscope (Bio-Rad).

Immunostaining of MEFs, IKKalpha -, and IKKbeta -deficient cells with a polyclonal antibody directed against beta -catenin demonstrated that beta -catenin has a different pattern of staining in IKKalpha -/- and IKKbeta -/- cells. beta -Catenin was present in both the nucleus and the cytoplasm of MEFs with marked accumulation at cell-cell junctions (Fig. 1B, panel A). In IKKalpha -/- cells, there was reduced nuclear staining of beta -catenin as compared with MEF cells (Fig. 1B, panel G). There was more beta -catenin present in the nucleus and the perinuclear region of IKKbeta -/- cells than in IKKalpha -/- cells (Fig. 1B, panel G). As a control, these cells were also stained with a monoclonal antibody directed against the basal transcription factor TFIIB, which is localized predominantly in the nucleus (Fig. 1B, panels B, E, and H). There was little background staining when the FITC-conjugated anti-goat secondary antibody was used with the mouse monoclonal antibody directed against TFIIB (Fig. 1B, panels C, F, and I). These results indicate that there is less beta -catenin localized in the nucleus of IKKalpha -/- cells than in either IKKbeta -/- cells or MEF cells.

beta -Catenin Activity in IKK-deficient Cells-- Next we addressed whether the differences in beta -catenin distribution in the IKK-deficient embryo fibroblasts could alter its transcriptional activity. The IKK-deficient cells and the parental MEFs were transfected with a TOPFLASH reporter construct alone or with expression vectors encoding either LEF-1 or beta -catenin. The TOPFLASH reporter is driven by four LEF/TCF binding motifs inserted upstream of a minimal c-fos promoter and a luciferase gene (15). As a control, the FOPFLASH reporter, which lacks LEF/TCF binding sites, was utilized. An RSV-beta -galactosidase expression vector was included in these transfections to control for differences in transfection efficiency.

When the TOPFLASH reporter alone was transfected into IKKalpha -/- cells, there was consistently a 5-6-fold lower level of activity as compared with that observed in IKKbeta -/- cells (Fig. 2). Transfection of an expression vector encoding LEF-1 into either IKKalpha -/- or IKKbeta -/- cells markedly stimulated TOPFLASH activity as did transfection of expression vectors encoding both LEF-1 and beta -catenin. There was no significant activity from the FOPFLASH reporter in either the absence or presence of beta -catenin and LEF-1 (Fig. 2). Transfection of expression vectors encoding wild-type IKKbeta and LEF-1 into IKKalpha -/- cells reduced TOPFLASH activity, while transfection of an IKKalpha expression vector with LEF-1 increased TOPFLASH activity in these cells (Fig. 2). When similar studies were performed in IKKbeta -/- cells, transfection of an IKKbeta expression vector reduced TOPFLASH activity, while transfection of an IKKalpha expression vector did not significantly alter TOPFLASH activity (Fig. 2). Transfection of both beta -catenin and LEF-1 resulted in similar levels of TOPFLASH activity in the IKKbeta -/- and IKKalpha -/- cells (Fig. 2). The parental MEF cells consistently gave somewhat higher TOPFLASH activity than seen in the IKK-deficient cells (Fig. 2). Again transfection of an IKKbeta expression vector with LEF-1 into these cells reduced TOPFLASH activity, while transfection of an IKKalpha expression vector with LEF-1 resulted in little change in TOPFLASH activity (Fig. 2). Thus, the reduced levels of endogenous beta -catenin in the nuclei of IKKalpha -/- cells are associated with decreased beta -catenin activation of gene expression, and this defect could be complemented by transfection of an IKKalpha expression vector. IKKalpha does not increase gene expression in the IKKbeta -/- and MEF cells, which have relatively abundant levels of nuclear beta -catenin.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 2.   beta -Catenin-mediated gene expression in IKKalpha - and IKKbeta -deficient cells. IKKalpha -/-, IKKbeta -/-, and MEFs were each cotransfected with either a TOPFLASH or FOPFLASH reporter (0.85 µg) and pCMV5 expression vectors encoding beta -catenin (0.5 µg), LEF-1 (50 ng), and either IKKalpha or IKKbeta (0.5 µg) as indicated and an RSV-beta -galactosidase reporter (0.60 µg) using LipofectAMINE Plus (Life Technologies, Inc.). All transfections contained 2.5 µg of DNA with a pCMV5 expression vector added to standardize DNA quantities. After 18 h, the cells were collected and lysed, both luciferase and beta -galactosidase activity was determined, and the normalized luciferase activity was calculated by correcting for differences in beta -galactosidase activity.

IKKbeta and IKKalpha Have Differential Effects on beta -Catenin Transactivation-- The results presented in the previous section suggested that IKKbeta and IKKalpha could potentially be involved in regulating the transcriptional stimulatory properties of beta -catenin. Thus it was important to address whether either IKKalpha or IKKbeta could alter beta -catenin-mediated transcriptional activation in COS cells, which have low levels of endogenous beta -catenin in the nucleus and relatively low levels of IKKalpha and IKKbeta (data not shown). COS cells were transfected with either a TOPFLASH or FOPFLASH reporter, LEF-1 and beta -catenin expression vectors, and increasing amounts of expression vectors encoding either the wild-type, constitutively active or kinase-defective mutants of IKKalpha and IKKbeta . The constitutively active IKK proteins (IKKalpha SS/EE and IKKbeta SS/EE) have glutamate substituted for serine residues in their T-loop so as to mimic phosphorylation of these residues and increase the activity of these kinases (30). The kinase-defective mutants (IKKalpha K/M and IKKbeta K/M) contain a substitution of a lysine residue at position 44 with methionine (30).

As previously demonstrated, the coexpression of beta -catenin and LEF-1 increased TOPFLASH but not FOPFLASH activity (Fig. 3A). When either wild-type IKKbeta or the constitutively activate kinase, IKKbeta SS/EE, was cotransfected with beta -catenin and LEF-1, TOPFLASH activity decreased in a concentration-dependent manner (Fig. 3A). In contrast, cotransfection of either wild-type IKKalpha or the constitutively active kinase, IKKalpha SS/EE, increased beta -catenin-dependent transactivation in a concentration-dependent manner (Fig. 3A). Transfection of the IKKbeta K/M mutant resulted in a modest decrease in beta -catenin transactivation that was not concentration-dependent, while transfection of the IKKalpha K/M mutant did not significantly alter beta -catenin transactivation (Fig. 3A).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Role of IKKalpha and IKKbeta in beta -catenin transactivation. A, the TOPFLASH reporter (0.75 µg) and expression vectors encoding LEF-1 (50 ng) and beta -catenin (0.7 µg) were cotransfected into COS cells in the presence of wild-type IKKalpha or IKKbeta , the constitutively active kinases, IKKbeta SS/EE and IKKalpha SS/EE, or the kinase-defective mutants, IKKbeta K/M and IKKalpha K/M, utilizing either 0.2, 0.5 or 1.0 µg of these kinases. B, COS cells were transfected with pCMV5 expression vectors encoding either HA-tagged wild-type (lanes 1-3) or the S33A/S37A mutant of beta -catenin (0.7 µg) and pCMV5 (1.0 µg) (lanes 1 and 3) or either wild-type or mutant beta -catenin together with an expression vector encoding the constitutively active FLAG-tagged IKKalpha (1.0 µg) (lanes 2 and 4) or FLAG-tagged IKKbeta (1.0 µg) (lanes 3 and 6). Whole cell extracts were prepared and subjected to Western blot analysis with the anti-HA monoclonal antibody 12CA5 to detect the HA-tagged beta -catenin (lanes 1-6, top panel) or the M2 monoclonal antibody directed against the FLAG-epitope to detect FLAG-tagged IKKalpha and IKKbeta (lanes 1-6, lower panel). C, the TOPFLASH reporter was cotransfected with expression vectors encoding LEF-1 and beta -catenin and the Ikappa Balpha super-repressor (0.1, 0.2 and 0.5 µg) vectors. In addition, the NF-kappa B luciferase reporter (100 ng) was transfected with expression vectors encoding either the constitutively active IKKbeta SS/EE or IKKalpha SS/EE and the Ikappa Balpha super-repressor. All COS cell transfections contained 0.5 µg of an RSV-beta -galactosidase expression vector, and the DNA amounts were standardized with a pCMV5 vector. Extracts were prepared 18 h after transfection, and the normalized luciferase activity was determined by correcting for differences in beta -galactosidase activity. The change in gene expression relative to the TOPFLASH reporter alone was determined for each transfection and the average of three experiments (each in duplicate) is shown.

The cotransfection experiments in COS cells indicated that IKKalpha increased beta -catenin-dependent gene expression, while IKKbeta decreased beta -catenin-dependent gene expression. Thus, we investigated whether IKKalpha and IKKbeta can alter beta -catenin protein levels. In addition, we asked whether IKKalpha and IKKbeta would affect the protein levels of a beta -catenin mutant in which serine residues 33 and 37 were changed to alanine to result in increased beta -catenin protein levels (15-17). Expression vectors encoding either the hemagglutinin-tagged wild-type or S33A/S37A mutant beta -catenin were transfected into COS cells either alone or in the presence of either the constitutively active FLAG-tagged IKKalpha or IKKbeta . Whole cell extracts were prepared from the transfected COS cells and analyzed by Western blot analysis using the 12CA5 and M2 monoclonal antibodies directed against the hemagglutinin and FLAG epitopes, respectively (Fig. 3B). IKKalpha expression increased the level of the epitope-tagged beta -catenin protein (Fig. 3B, lane 2), while IKKbeta reduced the amount of the epitope-tagged beta -catenin protein (Fig. 3B, lane 3). In contrast, IKKalpha did not alter the level of the S33A/S37A beta -catenin mutant (Fig. 3B, lane 5), while IKKbeta reduced the level of this protein (Fig. 3B, lane 6). Transfection assays with the TOPFLASH reporter indicated that IKKalpha increased gene expression in the presence of the wild-type but not the mutant beta -catenin, while IKKbeta reduced gene expression in the presence of both of these beta -catenin proteins (data not shown). These results suggest that IKKalpha either directly or indirectly may lead to increased levels of beta -catenin to increase TOPFLASH activity, while IKKbeta may reduce the levels of beta -catenin to decrease beta -catenin activity. The failure of IKKalpha to further increase the protein levels of the mutant beta -catenin suggests that the structure of the amino terminus of beta -catenin may be important in this process.

It was important to determine whether activation of the NF-kappa B pathway may be involved in the increased TOPFLASH activity seen in the presence of beta -catenin and LEF-1. The TOPFLASH reporter was transfected with expression vectors encoding beta -catenin, LEF-1, and the Ikappa Balpha super-repressor (Ikappa Balpha SS/AA) (Fig. 3C). The Ikappa Balpha super-repressor protein, which contains substitutions of serine residues 32 and 36 with alanine, cannot be phosphorylated by IKK, and its resistance to degradation prevents the nuclear translocation of the NF-kappa B proteins in response to activators of this pathway (27). The transfection of the Ikappa Balpha super-repressor did not alter activation of the TOPFLASH reporter in the presence of beta -catenin and LEF-1 expression vectors, while it completely abolished the activity of an NF-kappa B reporter (Fig. 3C). These results suggest that NF-kappa B activation does not appear to be involved in the activation of TOPFLASH activity by beta -catenin and LEF-1.

The Amino Terminus of beta -Catenin Is Critical for IKKalpha but Not IKKbeta Modulation of Gene Expression-- Next we addressed whether the same or different domains in beta -catenin were required for regulation by IKKalpha and IKKbeta . The amino terminus of beta -catenin is phosphorylated by GSK-3beta leading to beta -catenin degradation (50-52). Amino-terminal deletion mutants of beta -catenin are very stable because they lack sequences that are involved in APC-mediated degradation (50-54). Furthermore, our results suggested that the amino terminus of beta -catenin may be involved in IKKalpha -mediated regulation. To determine whether the amino terminus of beta -catenin was critical for mediating the effects of IKKalpha and IKKbeta , transfection of increasing amounts of a beta -catenin expression vector deleted of its first 129 amino acids was transfected into COS cells along with LEF-1. There was increased TOPFLASH activity seen with this mutant similar to the results seen with wild-type beta -catenin (Fig. 4). The expression of the constitutively active IKKbeta protein reduced activation of TOPFLASH reporter when transfected with this beta -catenin mutant. In contrast, the expression of the constitutively active IKKalpha protein did not alter the ability of the amino-terminal deletion of beta -catenin to activate the TOPFLASH reporter (Fig. 4). These results suggest that the decreased beta -catenin transactivation observed with IKKbeta is not dependent on the amino terminus of beta -catenin, while IKKalpha requires the presence of this domain to stimulate beta -catenin transcriptional activity.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   Differential effects of IKKbeta and IKKalpha on transactivation of an amino-terminal truncated beta -catenin. COS cells were cotransfected with the indicated plasmids including the TOPFLASH reporter, LEF-1, and either wild-type beta -catenin (group 1) or an amino-terminal deletion of the first 129 amino acids of beta -catenin (groups 2-4). The construct encoding the amino-terminal-deleted beta -catenin was cotransfected at concentrations of 0.5 (group 2), 1.0 (group 3), and 2.0 µg (group 4) together with the constitutively active kinases IKKbeta SS/EE (0.5 and 1.0 µg) and IKKalpha SS/EE (0.5 and 1.0 µg). An RSV-beta -galactosidase expression vector was added to each transfection, and DNA quantities were standardized by addition of a pCMV5 expression vector. After 18 h, the cells were collected and luciferase activity was determined and normalized to correct for differences in beta -galactosidase activity. The change in gene expression relative to the TOPFLASH reporter alone was determined for each transfection and the average of three experiments (each in duplicate) is presented.

beta -Catenin Interacts with IKKalpha and IKKbeta -- To address whether the effects of IKKalpha and IKKbeta on beta -catenin-dependent gene expression may be mediated by direct interactions with beta -catenin, we performed coimmunoprecipitation experiments of beta -catenin and the IKK proteins using cytoplasmic extracts prepared from the SW480 colon cancer cell line. SW480 cells express a truncated APC gene product and result in enhanced levels of beta -catenin. This increased level of beta -catenin was necessary to detect this protein in Western blot analysis of column fractions that were generated following chromatography (14).

Superdex-200 gel filtration chromatography of the S100 cytoplasmic extract prepared from SW480 cells was utilized to assay interactions between the IKK and beta -catenin. Similar chromatographic analysis has previously been used to characterize the high molecular weight IKK complex (55). Western blot analysis of these column fractions indicated that beta -catenin was present in a broad peak, including a portion that was present in high molecular weight fractions that also contained IKKalpha and IKKbeta (Fig. 5A, left panel). Column fractions 7-12, which contained both beta -catenin and the IKK proteins, were immunoprecipitated with a monoclonal antibody directed against beta -catenin followed by Western blot analysis with either beta -catenin, IKKalpha , or IKKbeta antibodies (Fig. 5A, middle panel). This analysis indicated that beta -catenin was associated with IKKalpha and IKKbeta , while immunoprecipitation of these column fractions with mouse IgG followed by Western blot analysis demonstrated no association of these proteins (Fig. 5A, right panel). These results suggest that endogenous beta -catenin can associate with IKKalpha and IKKbeta .


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 5.   Association of endogenous and transfected IKKalpha , IKKbeta and beta -catenin proteins. A, S100 extract was prepared from 108 SW480 cells and fractionated on a Superdex-200 gel filtration column. Equal volumes (40 µl) from each fraction were immunoblotted to monitor distribution of beta -catenin, IKKalpha , and IKKbeta (left panel). The mobility of the different protein markers on the Superdex-200 column are indicated as are the column fraction numbers. For association studies, equal volumes (200 µl) from column fractions 7-12, which contained the beta -catenin and the IKK proteins, were incubated overnight with monoclonal antibodies directed against beta -catenin (Transduction Laboratories). Western blot analysis was then performed on these immunoprecipitates using polyclonal goat antibody to detect beta -catenin or rabbit polyclonal antibodies to detect IKKalpha and IKKbeta (middle panel). These column fractions were also immunoprecipitated with mouse IgG followed by Western blot analysis with polyclonal antibodies directed against either beta -catenin, IKKalpha , or IKKbeta (right panel). B, COS cells were transfected using LipofectAMINE Plus with expression vectors encoding HA-tagged beta -catenin and either FLAG-tagged IKKalpha or FLAG-tagged IKKbeta . Cells were harvested 18 h after transfection, and S100 extracts were prepared and fractionated on a Superdex-200 column. Equal column volumes (40 µl) were subjected to Western blot analysis using 12CA5 antibody to detect HA-tagged beta -catenin (left and middle panels) or the M2 monoclonal antibody to detect FLAG-tagged IKKalpha (left panel) or FLAG-tagged IKKbeta (middle panel). Immunoprecipitation of column fractions prepared from FLAG-tagged IKKalpha and HA-tagged beta -catenin (left panel) or FLAG-tagged IKKbeta and HA-tagged beta -catenin (middle panel) transfected cells was performed using either the 12CA5 or M2 monoclonal antibodies followed by Western blot analysis with the antibody that was not used in the immunoprecipitation. Column fractions from extracts containing either FLAG-tagged IKKalpha and HA-tagged beta -catenin (right panel, first and third gels) or FLAG-tagged IKKbeta and HA-tagged beta -catenin (right panel, second and fourth gels) were immnoprecipitated with mouse IgG followed by Western blot analysis with either 12CA5 (HA) or M2 (FLAG) antibodies as indicated.

Next, we characterized the interactions of IKKalpha and IKKbeta with beta -catenin following cotransfection of COS cells with expression vectors encoding these epitope-tagged proteins (Fig. 5B). First, S100 extracts prepared from these cells were subjected to Superdex-200 chromatography and Western blot analysis. As previously noted, when IKKalpha and IKKbeta were transfected into COS cells they migrate in a relatively broad peak following Superdex-200 chromatography due to the failure to completely assemble into the high molecular weight IKK complex (49) (Fig. 5B, left and middle panels). Next, immunoprecipitation of column fractions prepared from extracts containing the FLAG-tagged IKKalpha and HA-tagged beta -catenin was performed followed by Western blotting. This analysis indicated that FLAG-tagged IKKalpha and HA-tagged beta -catenin were able to associate (Fig. 5B, left panel). Column fractions of extracts prepared from COS cells cotransfected with FLAG-tagged IKKbeta and HA-tagged beta -catenin indicated that both of these proteins were also able to associate (Fig. 5B, middle panel). Western blot analysis of the immunoprecipitated IKK and beta -catenin proteins do not strictly overlap. This is likely due to the fact that their elution profiles following chromatography vary, which is consistent with the presence of these proteins in multiple complexes. The column fractions containing HA-tagged beta -catenin and either FLAG-tagged IKKalpha or IKKbeta were also immunoprecipitated with mouse IgG and analyzed by Western blot analysis. This analysis revealed that there were not nonspecific associations of the beta -catenin and IKK proteins (Fig. 5B, right panel).

To further characterize the interactions of beta -catenin with IKKalpha and IKKbeta , in vitro binding of SW480 cytoplasmic extract with GST proteins fused to different domains of beta -catenin was performed. Thus, we could determine the role of different domains of beta -catenin including the amino terminus, which regulates protein stability, the armadillo repeats, and the C-terminal transactivation domain in binding the IKK proteins (53). Following the incubation of the SW480 cytoplasmic extract with the GST-beta -catenin fusion proteins bound to glutathione-Sepharose beads, Western analysis was performed with antibodies directed against either IKKalpha or IKKbeta . Each of the beta -catenin fusion proteins, but not GST alone, was able to interact with IKKalpha and IKKbeta (Fig. 6B). However, the GST-beta -catenin fusion proteins extending between amino acid residues 1-400 and 130-400 consistently bound more IKKalpha and IKKbeta (Fig. 6B). These results suggested that the region of beta -catenin containing the first six armadillo repeats was probably critical for interaction with the IKK proteins. The data from the GST-pull down assays in conjunction with coimmunoprecipitation data of both endogenous and transfected proteins demonstrate that the IKK proteins and beta -catenin can interact under a variety of different conditions.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 6.   In vitro interaction of beta -catenin with endogenous IKKalpha and IKKbeta . A, a schematic representation of the GST beta -catenin fusion proteins that were used to analyze interactions with SW480 extract is shown. B, GST-fusion proteins with beta -catenin were bound to glutathione-Sepharose beads (lanes 1-6), and after overnight incubation with SW480 cell extract, the glutathione beads were extensively washed and Western blot analysis was performed using rabbit polyclonal antibodies directed against either IKKalpha or IKKbeta as indicated. 10% of the SW480 lysate alone is shown in lane 7. C, the GST-fusion proteins were analyzed by Coomassie Blue staining.

IKKalpha and IKKbeta Phosphorylate beta -Catenin-- Next we addressed whether IKK could phosphorylate the amino terminus of beta -catenin and whether stimulation of IKK activity could result in increased beta -catenin phosphorylation in in vitro kinase assays. The amino terminus of beta -catenin has been demonstrated to be a target for GSK-3beta phosphorylation (9), while serine residues 32 and 36 in the amino terminus of GST-Ikappa Balpha are the target for IKK phosphorylation (29-33). HeLa cells were either untreated, treated with TNFalpha , or transfected with an expression vector encoding NIK (56, 57) to induce IKK kinase activity. The IKK complex was immunoprecipitated from extracts prepared from these cells and assayed for its ability to phosphorylate either GST-beta -cat-(1-91), GST-Ikappa Balpha -(1-54), or GST-Ikappa Balpha (SS/AA)-(1-54). IKK activity was induced by treatment with either TNFalpha or NIK and increased the phosphorylation of beta -catenin (Fig. 7A, lanes 1-3) and Ikappa Balpha (Fig. 7A, lanes 4-6), but not the Ikappa Balpha mutant in which serine residues 32 and 36 were changed to alanine (Fig. 7A, lanes 7-9).


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 7.   IKKalpha and IKKbeta phosphorylate beta -catenin and Ikappa Balpha . A, HeLa cells were either untreated, treated with TNFalpha (20 ng/ml) for 10 min, or transfected with a pCMV5 expression vector encoding NIK. Extracts were immunoprecipitated with a polyclonal antibody directed against IKKalpha and IKKbeta and in vitro kinase assays were performed with GST fusions with beta -catenin-(1-91), Ikappa Balpha -(1-54) or Ikappa Balpha SS/AA-(1-54) followed by autoradiography. B, recombinant baculovirus-expressed IKKalpha and IKKbeta proteins were purified as described. In vitro kinase assays were performed using IKKalpha and IKKbeta and GST-beta -cat-(1-91) (lanes 1 and 4) and GST-Ikappa Balpha -(1-54) (lanes 2 and 5) as substrates (upper panel). A GST-Ikappa Balpha protein in which serine residues 32 and 36 were changed to alanine (lanes 3 and 6) was also assayed. The GST fusion proteins used in the in vitro kinase assay were monitored by Coomassie Blue staining (lower panel). C, COS cells were transfected with expression vectors encoding either FLAG-tagged wild-type or mutant IKKalpha or IKKbeta kinases or mock transfected (no kinase). After 30 h, the cells were collected, and cellular extract was immunoprecipitated with the M2 monoclonal antibody directed against FLAG-epitope. The upper panel demonstrates in vitro phosphorylation of either GST-beta -catenin (lanes 1, 4, 7, 10, and 13), GST-Ikappa Balpha (lanes 2, 5, 8, 11, and 14) or no added substrate (lanes 3, 6, 9, 12, and 15) by the indicated kinases. Expression of the transfected IKK constructs was analyzed by Western blot analysis (middle panel). Immunoprecipitation of extracts from mock-transfected cells were also analyzed in in vitro kinase assays (lanes 13-15). The amount of GST-beta -catenin and GST-Ikappa Balpha substrates used in these assays was monitored by Coomassie Blue staining (lower panel). D, FLAG-tagged IKKalpha (top panel) and IKKbeta (bottom panel) immunoprecipitated from COS cell extracts were used in in vitro kinase assays with GST alone (lane 1) or GST fusions containing Ikappa Balpha -(1-54) (lane 2), beta -catenin-(1-91) (lane 3), beta -catenin-(1-781) (lane 4), or beta -catenin-(130-781) (lane 5). SDS-PAGE and autoradiography were then performed. A Coomassie-stained gel of the substrates used in the in vitro kinase assays is shown in the right panel.

Recombinant baculovirus-produced IKKalpha and IKKbeta were also tested in in vitro kinase assays using GST fusions with beta -catenin or Ikappa Balpha . Both IKKalpha and IKKbeta also phosphorylated the amino terminus of beta -catenin and Ikappa Balpha , but not the Ikappa Balpha mutant (Fig. 7B). COS cells were next transfected with either epitope-tagged wild-type or mutant IKKalpha and IKKbeta , and following immunoprecipitation with the M2 monoclonal antibody these kinases were assayed using in vitro kinase assays with beta -catenin and Ikappa Balpha as substrates (48). Wild-type IKKalpha and IKKbeta , but not the kinase-defective mutants, were able to phosphorylate beta -catenin and Ikappa Balpha (Fig. 7C).

Finally, we addressed whether IKKalpha and IKKbeta could also phosphorylate additional regions in beta -catenin other than its amino terminus (Fig. 7D). Both kinases phosphorylated GST fusion proteins containing various portions of beta -catenin (Fig. 7D, lanes 2-5). These GST fusions contained either the amino terminus of beta -catenin, an amino-terminal-deleted form of beta -catenin or full-length beta -catenin (Fig. 7D). Similar results were obtained using IKKalpha and IKKbeta preparations produced by baculovirus expression (data not shown). These results indicate that both IKKalpha and IKKbeta phosphorylate multiple regions of beta -catenin.

Stoichiometry of IKK Phosphorylation of Ikappa Balpha and beta -Catenin-- Next we compared the ability of IKKalpha and IKKbeta to phosphorylate GST-Ikappa Balpha -(1-54) and GST-beta -cat-(1-91) substrates. In these in vitro kinase assays, we analyzed the phosphorylation of each of these substrates at specific points over a 120-min time course utilizing 0.01 mM, 0.1 mM, and 1.0 mM of cold ATP and 15 µCi of [gamma -32]ATP. Following SDS-PAGE and autoradiography (Figs. 8A and 8B, top panels), the 32P-incorporation into the beta -catenin and Ikappa Balpha substrates was determined, and the number of the moles of phosphate incorporated per mole of substrate was calculated (Fig. 8, A and B, lower panels).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 8.   Stoichiometry of phosphate incorporation into the amino termini of Ikappa Balpha and beta -catenin by IKKalpha and IKKbeta . A, FLAG-tagged IKKalpha and B, IKKbeta were immunoprecipitated from COS extracts with the M2 monoclonal antibody and incubated with 2 µg of GST fusions containing either beta -catenin-(1-91) or Ikappa Balpha -(1-54) in kinase buffer containing 15 µCi of [gamma -32P]ATP with a specific activity of 6000 Ci/mM and cold ATP at concentrations of 1 mM, 0.1 mM, and 0.01 mM. In vitro kinase reactions were performed for 0, 5, 15, 30, 60, and 120 min at 30 °C, and the samples were subjected to SDS-PAGE and autoradiography (A and B, top panels). Incorporation of 32P into these substrates was quantitated by scintillation counting and the moles of phosphate incorporated per mole of substrate was calculated (A and B, bottom panels).

Kinase assays performed with IKKalpha using 1 mM of cold ATP resulted in ~0.05 mol of phosphate/mol of protein incorporated into the amino terminus of beta -catenin as compared with 0.09 mol of phosphate/mol of protein incorporated into the amino terminus of Ikappa Balpha after a 120-min reaction (Fig. 8A). Kinase assays performed with IKKbeta using 1 mM of cold ATP demonstrated that there was 1.4 mol of phosphate/mol of protein incorporated into the amino terminus of beta -catenin and 0.5 mol of phosphate/mol of protein incorporated in the amino terminus of Ikappa Balpha after 120 min (Fig. 8B). It is interesting to note that the phosphorylation of the beta -catenin by IKKbeta may be biphasic in contrast to its phosphorylation of Ikappa Balpha (Fig. 8B). Similar phosphate incorporation into these substrates was found using both baculovirus-produced and COS-transfected IKKalpha and IKKbeta proteins (data not shown). In agreement with previous studies, this analysis indicates that IKKalpha is a much weaker kinase than is IKKbeta in phosphorylating Ikappa Balpha (58) and beta -catenin. These results indicate that the IKK proteins result in relatively similar incorporation of phosphate into the amino terminus of beta -catenin and Ikappa Balpha , although there are differences in the kinetics of this process.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In this study, we present data that IKKalpha and IKKbeta can modulate beta -catenin function. First, we observed the differential localization of beta -catenin in mouse embryo fibroblasts derived from IKKalpha - and IKKbeta -deficient cells. Second, the transcriptional activity of beta -catenin was higher in IKKbeta -/- cells as compared with IKKalpha -/- cells. Third, IKKbeta decreased beta -catenin-dependent gene expression similar to the effects seen with GSK-3beta , while IKKalpha increased this activity. Fourth, we found that IKKalpha expression in COS cells increased the amount of beta -catenin, while IKKbeta expression reduced the amount of beta -catenin. Finally, we demonstrated that IKKalpha and IKKbeta interacted with and were able to phosphorylate beta -catenin. Experiments are underway to map the sites in beta -catenin that are phosphorylated by IKKalpha and IKKbeta in order to determine whether phosphorylation alters beta -catenin function. Our preliminary results suggest that IKKalpha phosphorylates different residues in the amino terminus of beta -catenin than serine residues 33 and 37 that are phosphorylated by GSK-3beta .

Studies with an amino-terminal deletion of beta -catenin indicated that IKKalpha requires this region to increase beta -catenin-dependent gene expression, while the effects of IKKbeta on beta -catenin activity are not dependent on this region. These results and the finding that IKKalpha is not able to increase the protein levels of an amino-terminal beta -catenin mutant suggest that the amino terminus of beta -catenin is likely involved in IKKalpha regulation. Thus, IKKalpha and IKKbeta likely have effects on different domains of beta -catenin to alter its role on gene expression. It is unclear whether differences in the kinase activity of IKKalpha and IKKbeta are involved in their differential effects on beta -catenin-dependent gene expression or whether other effects such as differential binding to specific pools of beta -catenin may be involved. Finally, additional mechanisms such as IKK effects on beta -catenin protein stability and/or nuclear import or export are possible. Multiple factors including Wnt signaling, the TCF/LEF proteins (19, 52, 53), and APC (59) affect the cellular localization of beta -catenin, which lacks a canonical nuclear localization signal. Although we demonstrate that the IKK proteins interact with beta -catenin, it is possible that IKK interaction with other components of the Wnt pathway such as APC may also be involved in regulating beta -catenin function.

Both IKKalpha and IKKbeta can form heterodimers and homodimers, and dimerization of these kinases is essential for their activity (33, 47, 60, 61). However, previous data has suggested that there is no synergy between IKKalpha and IKKbeta in regulating their kinase activity (58). Given the wide disparity in their kinase activity, they may have other cellular targets in addition to Ikappa B (58). The ability of these kinases to potentially associate with as yet unidentified cellular factors may alter their substrate specificity. Gene disruption studies indicate that IKKbeta rather than IKKalpha is the critical kinase involved in the activation of the NF-kappa B pathway in response to treatment with either TNFalpha or IL-1beta (37-39). The predominant cytoplasmic localization of IKKbeta probably reflects the major role of this kinase in the phosphorylation of the Ikappa B proteins that are localized in the cytoplasm bound to the RelA/p65 NF-kappa B protein (37-39). The results of our immunofluorescence studies suggest that IKKalpha is localized in both the nucleus and cytoplasm of MEFs and may be predominantly nuclear in the absence of IKKbeta in IKKbeta -/- cells. Consistent with these observations, Western blot analysis of extracts prepared from COS cells transfected with expression vectors encoding IKKalpha and IKKbeta indicate that IKKbeta is predominantly localized in the cytoplasm, while IKKalpha is present in both the nucleus and the cytoplasm. Additional studies are currently underway to better characterize the cellular localization of IKKalpha . Whether any of the effects of IKKalpha on skin and skeletal development may in part be mediated by either IKKalpha binding and/or phosphorylation of beta -catenin remains to be determined.

IKK regulation of beta -catenin activity differs from its activation of the NF-kappa B pathway. Cytokines such as TNFalpha stimulate IKK phosphorylation of Ikappa B leading to its rapid degradation and the nuclear translocation of NF-kappa B. TNFalpha activation of an NF-kappa B reporter construct is blocked by transfection of an IKKbeta dominant negative mutant (30). Although TNFalpha treatment of cells results in marked decreases in beta -catenin-dependent gene expression, this effect is only partially blocked by an IKKbeta dominant negative mutant. These results suggest that the effects of TNFalpha on beta -catenin-dependent gene expression likely involve additional substrates and/or pathways other than IKKbeta and beta -catenin. Although our results support a role for IKKalpha and IKKbeta on modulating beta -catenin activity, the regulation of this pathway is different from that seen with TNFalpha -induction of IKK to activate the NF-kappa B pathway.

Several observations are also consistent with the potential for similar factors being involved in the regulation of the Wnt and NF-kappa B pathways. It has been demonstrated that beta -catenin/TCF signaling increases beta -TrCP levels by a posttranscriptional mechanism to result in increased degradation of both beta -catenin and Ikappa B (45). Thus, changes of beta -TrCP levels can result in marked effects on both the beta -catenin and NF-kappa B pathways. Additionally, GSK-3beta , which is an important kinase involved in regulating beta -catenin levels, has also been implicated in regulating NF-kappa beta activation. Gene disruption studies have indicated that GSK-3beta -/- mice have a phenotype similar to IKKbeta -deficient mice developing liver degeneration as a result of increased sensitivity to TNFalpha stimulation (46). The mechanism by which GSK-3beta may alter the NF-kappa B pathway remains to be determined. In summary, our studies suggest that a common set of cellular factors may be involved in the integration of a variety of cellular signaling processes that regulate the NF-kappa B and beta -catenin pathways.

    ACKNOWLEDGEMENTS

We thank Ken Kinzler for providing beta -catenin and the TOPFLASH reporter constructs, Rudolf Grosschedl for providing the expression vector encoding LEF-1, Masahiro Aoki for providing additional LEF constructs, and Xiaodong Wang for providing the MEF cells. We also thank Melanie Cobb for helpful suggestions and Sharon Johnson and Alex Herrera for preparation of the manuscript and figures, respectively.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA 74128.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

** To whom correspondence should be addressed: Div. of Hematology-Oncology, Dept. of Medicine, Univ. of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8594. Tel.: 214-648-4996; Fax: 214-648-4152; E-mail: gaynor@utsw.swmed.edu.

Published, JBC Papers in Press, August 29, 2001, DOI 10.1074/jbc.M104227200

    ABBREVIATIONS

The abbreviations used are: Wnt, Wingless; APC, adenomatous polyposis coli tumor suppressor protein; TCF, T-cell factor; LEF, lymphocyte-enhancer factor; NFkappa B, nuclear factor kappa B; IKK, Ikappa B kinase; MEF, mouse embryo fibroblast; FITC, fluorescein isothiocyanate; NIK, NF-kappa B inducing kinase; GST, glutathione S-transferase; PCR, polymerase chain reaction; HA, hemagglutinin; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Kemler, R. (1993) Trends Genet. 9, 317-321[CrossRef][Medline] [Order article via Infotrieve]
2. Ben-Ze'ev, A., and Geiger, B. (1998) Curr. Opin. Cell Biol. 10, 629-639[CrossRef][Medline] [Order article via Infotrieve]
3. Peifer, M., and Wieschaus, E. (1990) Cell 63, 1167-1176[CrossRef][Medline] [Order article via Infotrieve]
4. McCrea, P. D., Brieher, W. M., and Gumbiner, B. M. (1993) J. Cell Biol. 123, 477-484[Abstract/Free Full Text]
5. Funayama, N., Fagotto, F., McCrea, P., and Gumbiner, B. M. (1995) J. Cell Biol. 128, 959-968[Abstract/Free Full Text]
6. Heasman, J., Crawford, A., Goldstone, K., Garner-Hamrick, P., Gumbiner, B., McCrea, P., Kintner, C., Noro, C. Y., and Wylie, C. (1994) Cell 79, 791-803[CrossRef][Medline] [Order article via Infotrieve]
7. Laurent, M. N., Blitz, I. L., Hashimoto, C., Rothbacher, U., and Cho, K. W. (1997) Development 124, 4905-4916[Abstract]
8. Morin, P. J. (1999) Bioessays 21, 1021-1030[CrossRef][Medline] [Order article via Infotrieve]
9. Polakis, P. (2000) Genes Dev. 14, 1837-1851[Free Full Text]
10. Laney, J. D., and Hochstrasser, M. (1999) Cell 97, 427-430[CrossRef][Medline] [Order article via Infotrieve]
11. Maniatis, T. (1999) Genes Dev. 13, 505-510[Free Full Text]
12. Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S. H., Masiarz, F. R., Munemitsu, S., and Polakis, P. (1993) Science 262, 1731-1734[Abstract/Free Full Text]
13. Su, L. K., Vogelstein, B., and Kinzler, K. W. (1993) Science 262, 1734-1737[Abstract/Free Full Text]
14. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3046-3050[Abstract/Free Full Text]
15. Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., and Clevers, H. (1997) Science 275, 1784-1787[Abstract/Free Full Text]
16. Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. (1997) Science 275, 1787-1790[Abstract/Free Full Text]
17. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997) Science 275, 1790-1792[Abstract/Free Full Text]
18. Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. (1996) Nature 382, 638-642[CrossRef][Medline] [Order article via Infotrieve]
19. Huber, O., Korn, R., McLaughlin, J., Ohsugi, M., Herrmann, B. G., and Kemler, R. (1996) Mech. Dev. 59, 3-10[CrossRef][Medline] [Order article via Infotrieve]
20. Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O., and Clevers, H. (1996) Cell 86, 391-399[CrossRef][Medline] [Order article via Infotrieve]
21. Brunner, E., Peter, O., Schweizer, L., and Basler, K. (1997) Nature 385, 829-833[CrossRef][Medline] [Order article via Infotrieve]
22. Giese, K., and Grosschedl, R. (1993) EMBO J. 12, 4667-4676[Medline] [Order article via Infotrieve]
23. Giese, K., Kingsley, C., Kirshner, J. R., and Grosschedl, R. (1995) Genes Dev. 9, 995-1008[Abstract/Free Full Text]
24. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Science 281, 1509-1512[Abstract/Free Full Text]
25. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R., and Ben-Ze'ev, A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 5522-5527[Abstract/Free Full Text]
26. Tetsu, O., and McCormick, F. (1999) Nature 398, 422-426[CrossRef][Medline] [Order article via Infotrieve]
27. Baldwin, A. S. (1996) Annu. Rev. Immunol. 14, 649-681[CrossRef][Medline] [Order article via Infotrieve]
28. Ghosh, S., May, M. J., and Kopp, E. B. (1998) Annu. Rev. Immunol. 16, 225-260[CrossRef][Medline] [Order article via Infotrieve]
29. DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997) Nature 388, 548-554[CrossRef][Medline] [Order article via Infotrieve]
30. Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J., Young, D. B., Barbosa, M., and Mann, M. (1997) Science 278, 860-866[Abstract/Free Full Text]
31. Regnier, C. H., Song, H. Y., Gao, X., Goeddel, D. V., Cao, Z., and Rothe, M. (1997) Cell 90, 373-383[CrossRef][Medline] [Order article via Infotrieve]
32. Woronicz, J. D., Gao, X., Cao, Z., Rothe, M., and Goeddel, D. V. (1997) Science 278, 866-869[Abstract/Free Full Text]
33. Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) Cell 91, 243-252[CrossRef][Medline] [Order article via Infotrieve]
34. Rothwarf, D. M., Zandi, E., Natoli, G., and Karin, M. (1998) Nature 395, 297-300[CrossRef][Medline] [Order article via Infotrieve]
35. Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk, H. E., Kay, R. J., and Israel, A. (1998) Cell 93, 1231-1240[CrossRef][Medline] [Order article via Infotrieve]
36. Mercurio, F., Murray, B. W., Shevchenko, A., Bennett, B. L., Young, D. B., Li, J. W., Pascual, G., Motiwala, A., Zhu, H., Mann, M., and Manning, A. M. (1999) Mol. Cell. Biol. 19, 1526-1538[Abstract/Free Full Text]
37. Li, Z. W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M., Johnson, R., and Karin, M. (1999) J. Exp. Med. 189, 1839-1845[Abstract/Free Full Text]
38. Tanaka, M., Fuentes, M. E., Yamaguchi, K., Durnin, M. H., Dalrymple, S. A., Hardy, K. L., and Goeddel, D. V. (1999) Immunity 10, 421-429[CrossRef][Medline] [Order article via Infotrieve]
39. Li, Q., Van Antwerp, D., Mercurio, F., Lee, K. F., and Verma, I. M. (1999) Science 284, 321-325[Abstract/Free Full Text]
40. Hu, Y., Baud, V., Delhase, M., Zhang, P., Deerinck, T., Ellisman, M., Johnson, R., and Karin, M. (1999) Science 284, 316-320[Abstract/Free Full Text]
41. Takeda, K., Takeuchi, O., Tsujimura, T., Itami, S., Adachi, O., Kawai, T., Sanjo, H., Yoshikawa, K., Terada, N., and Akira, S. (1999) Science 284, 313-316[Abstract/Free Full Text]
42. Li, Q., Lu, Q., Hwang, J. Y., Buscher, D., Lee, K. F., Izpisua-Belmonte, J. C., and Verma, I. M. (1999) Genes Dev. 13, 1322-1328[Abstract/Free Full Text]
43. Karin, M., and Ben-Neriah, Y. (2000) Annu Rev of Immunol. 18, 621-663[CrossRef][Medline] [Order article via Infotrieve]
44. Winston, J. T., Strack, P., Beer-Romero, P., Chu, C., Elledge, S. J., and Harper, J. W. (1999) Genes Dev. 13, 270-283[Abstract/Free Full Text]
45. Spiegelman, V. S., Slaga, T. J., Pagano, M., Minamoto, T., Ronai, Z., and Fuchs, S. Y. (2000) Mol. Cell 5, 877-882[CrossRef][Medline] [Order article via Infotrieve]
46. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O., and Woodgett, J. R. (2000) Nature 406, 86-90[CrossRef][Medline] [Order article via Infotrieve]
47. Kwak, Y. T., Guo, J., Shen, J., and Gaynor, R. B. (2000) J. Biol. Chem. 275, 14752-14759[Abstract/Free Full Text]
48. Yamamoto, Y., Yin, M. J., and Gaynor, R. B. (2000) Mol. Cell. Biol. 20, 3655-3666[Abstract/Free Full Text]
49. Li, X.-H., Murphy, K. M., Palka, K. T., Surabhi, R. M., and Gaynor, R. B. (1999) J. Biol. Chem. 274, 34417-34424[Abstract/Free Full Text]
50. Munemitsu, S., Albert, I., Rubinfeld, B., and Polakis, P. (1996) Mol. Cell. Biol. 16, 4088-4094[Abstract]
51. Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D., and Moon, R. T. (1996) Genes Dev. 10, 1443-1454[Abstract/Free Full Text]
52. Pai, L. M., Orsulic, S., Bejsovec, A., and Peifer, M. (1997) Development 124, 2255-2266[Abstract],
53. Hsu, S. C., Galceran, J., and Grosschedl, R. (1998) Mol. Cell. Biol. 18, 4807-4818[Abstract/Free Full Text]
54. Wong, M. H., Rubinfeld, B., and Gordon, J. I. (1998) J. Cell Biol. 141, 765-777[Abstract/Free Full Text]
55. Chen, Z. J., Parent, L., and Maniatis, T. (1996) Cell 84, 853-862[CrossRef][Medline] [Order article via Infotrieve]
56. Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. (1997) Nature 385, 540-548[CrossRef][Medline] [Order article via Infotrieve]
57. Nemoto, S., DiDonato, J. A., and Lin, A. (1998) Mol. Cell. Biol. 18, 7336-7343[Abstract/Free Full Text]
58. Li, J., Peet, G. W., Pullen, S. S., Schembri-King, J., Warren, T. C., Marcu, K. B., Kehry, M. R., Barton, R., and Jakes, S. (1998) J. Biol. Chem. 273, 30736-30741[Abstract/Free Full Text]
59. Rosin-Arbesfeld, R., Townsley, F., and Blenz, M. (2000) Nature 406, 1009-1012[CrossRef][Medline] [Order article via Infotrieve]
60. Zandi, E., Chen, Y., and Karin, M. (1998) Science 281, 1360-1363[Abstract/Free Full Text]
61. Delhase, M., Hayakawa, M., Chen, Y., and Karin, M. (1999) Science 284, 309-313[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
T. Hideshima, D. Chauhan, T. Kiziltepe, H. Ikeda, Y. Okawa, K. Podar, N. Raje, A. Protopopov, N. C. Munshi, P. G. Richardson, et al.
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Blood, May 21, 2009; 113(21): 5228 - 5236.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Xia, R. C. Padre, T. H. De Mendoza, V. Bottero, V. B. Tergaonkar, and I. M. Verma
Phosphorylation of p53 by I{kappa}B kinase 2 promotes its degradation by {beta}-TrCP
PNAS, February 24, 2009; 106(8): 2629 - 2634.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D.-F. Lee and M.-C. Hung
Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy
Clin. Cancer Res., September 15, 2008; 14(18): 5656 - 5662.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
M. Hiremath, J. P. Lydon, and P. Cowin
The pattern of {beta}-catenin responsiveness within the mammary gland is regulated by progesterone receptor
Development, October 15, 2007; 134(20): 3703 - 3712.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C. L. Avvisato, X. Yang, S. Shah, B. Hoxter, W. Li, R. Gaynor, R. Pestell, A. Tozeren, and S. W. Byers
Mechanical force modulates global gene expression and beta-catenin signaling in colon cancer cells
J. Cell Sci., August 1, 2007; 120(15): 2672 - 2682.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Li, Z. Wang, D. Kong, S. Murthy, Q. P. Dou, S. Sheng, G. P. V. Reddy, and F. H. Sarkar
Regulation of FOXO3a/beta-Catenin/GSK-3beta Signaling by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells
J. Biol. Chem., July 20, 2007; 282(29): 21542 - 21550.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. F. Liu and A. B. Malik
NF-{kappa}B activation as a pathological mechanism of septic shock and inflammation
Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L622 - L645.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-T. Kwak, R. Li, C. R. Becerra, D. Tripathy, E. P. Frenkel, and U. N. Verma
I{kappa}B Kinase {alpha} Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation
J. Biol. Chem., October 7, 2005; 280(40): 33945 - 33952.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Lee, C. Andrieu, F. Saltel, O. Destaing, J. Auclair, V. Pouchkine, J. Michelon, B. Salaun, R. Kobayashi, P. Jurdic, et al.
I{kappa}B kinase {beta} phosphorylates Dok1 serines in response to TNF, IL-1, or {gamma} radiation
PNAS, December 14, 2004; 101(50): 17416 - 17421.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
Y. Guan, N. M. Rubenstein, K. L. Failor, P. L. Woo, and G. L. Firestone
Glucocorticoids Control {beta}-Catenin Protein Expression and Localization through Distinct Pathways that Can Be Uncoupled by Disruption of Signaling Events Required for Tight Junction Formation in Rat Mammary Epithelial Tumor Cells
Mol. Endocrinol., January 1, 2004; 18(1): 214 - 227.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
X. Wang, N. Adhikari, Q. Li, Z. Guan, and J. L. Hall
The Role of {beta}-Transducin Repeat-Containing Protein ({beta}-TrCP) in the Regulation of NF-{kappa}B in Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 85 - 90.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Provost, Y. Yamamoto, I. Lizardi, J. Stern, T. G. D'Aquila, R. B. Gaynor, and D. L. Rimm
Functional Correlates of Mutations in {beta}-Catenin Exon 3 Phosphorylation Sites
J. Biol. Chem., August 22, 2003; 278(34): 31781 - 31789.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
K. De Bosscher, W. Vanden Berghe, and G. Haegeman
The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression
Endocr. Rev., August 1, 2003; 24(4): 488 - 522.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
U. N. Verma, R. M. Surabhi, A. Schmaltieg, C. Becerra, and R. B. Gaynor
Small Interfering RNAs Directed against {beta}-Catenin Inhibit the in Vitro and in Vivo Growth of Colon Cancer Cells
Clin. Cancer Res., April 1, 2003; 9(4): 1291 - 1300.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C. Fan, J. Yang, and J. F. Engelhardt
Temporal pattern of NF{kappa}B activation influences apoptotic cell fate in a stimuli-dependent fashion
J. Cell Sci., March 14, 2003; 115(24): 4843 - 4853.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
C. Albanese, K. Wu, M. D'Amico, C. Jarrett, D. Joyce, J. Hughes, J. Hulit, T. Sakamaki, M. Fu, A. Ben-Ze'ev, et al.
IKKalpha Regulates Mitogenic Signaling through Transcriptional Induction of Cyclin D1 via Tcf
Mol. Biol. Cell, February 1, 2003; 14(2): 585 - 599.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Holnthoner, M. Pillinger, M. Groger, K. Wolff, A. W. Ashton, C. Albanese, P. Neumeister, R. G. Pestell, and P. Petzelbauer
Fibroblast Growth Factor-2 Induces Lef/Tcf-dependent Transcription in Human Endothelial Cells
J. Biol. Chem., November 22, 2002; 277(48): 45847 - 45853.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. S. Russell, U. Raju, G. J. Gumin, F. F. Lang, D. R. Wilson, T. Huet, and P. J. Tofilon
Inhibition of Radiation-induced Nuclear Factor-{kappa}B Activation by an Anti-Ras Single-Chain Antibody Fragment: Lack of Involvement in Radiosensitization
Cancer Res., April 1, 2002; 62(8): 2318 - 2326.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/45/42276    most recent
M104227200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamberti, C.
Right arrow Articles by Gaynor, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamberti, C.
Right arrow Articles by Gaynor, R. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement